CONMED (NYSE:CNMD) Issues FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Monday. The company provided earnings per share guidance of 4.250-4.450 for the period, compared to the consensus earnings per share estimate of 4.460. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Ratings Changes

CNMD has been the subject of a number of research reports. Wells Fargo & Company dropped their price target on CONMED from $57.00 to $47.00 and set an “equal weight” rating for the company in a research note on Thursday, November 6th. Piper Sandler dropped their target price on CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Zacks Research lowered CONMED from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lowered their price objective on CONMED from $58.00 to $52.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $53.67.

CONMED Trading Down 0.6%

Shares of CONMED stock traded down $0.25 on Monday, hitting $42.66. 15,846 shares of the company’s stock traded hands, compared to its average volume of 573,573. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of 20.81, a price-to-earnings-growth ratio of 2.83 and a beta of 0.96. The company has a fifty day moving average of $42.05 and a two-hundred day moving average of $47.52. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.10 and a quick ratio of 0.95. CONMED has a one year low of $38.32 and a one year high of $74.70.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.08 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The business had revenue of $337.93 million during the quarter, compared to analyst estimates of $334.76 million. CONMED had a net margin of 4.75% and a return on equity of 14.22%. CONMED’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.05 EPS. CONMED has set its FY 2025 guidance at 4.480-4.530 EPS. As a group, sell-side analysts expect that CONMED will post 4.35 earnings per share for the current year.

Institutional Investors Weigh In On CONMED

Several hedge funds have recently bought and sold shares of CNMD. Dimensional Fund Advisors LP boosted its holdings in shares of CONMED by 19.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock valued at $60,984,000 after buying an additional 214,126 shares in the last quarter. Wasatch Advisors LP purchased a new stake in CONMED during the 3rd quarter valued at about $47,026,000. Deerfield Management Company L.P. raised its holdings in CONMED by 8.6% in the third quarter. Deerfield Management Company L.P. now owns 760,196 shares of the company’s stock worth $35,752,000 after buying an additional 59,925 shares during the last quarter. Glenmede Investment Management LP lifted its stake in shares of CONMED by 14.0% in the third quarter. Glenmede Investment Management LP now owns 222,136 shares of the company’s stock worth $10,447,000 after buying an additional 27,337 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of CONMED during the third quarter valued at approximately $9,239,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.